We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back to Event-Details

WHO/Swissmedic Signature Session - Towards Access 2030: How Can Strengthening of Regulatory Systems Contribute?

Track:
Hot Topic/Stand Alone

Day & Time:
April 17, 9:00AM - 10:30AM (Central Europe Standard Time)

Session Number:
SAT1

Room Number:
Montreal

Type:
Session

Title:
WHO/Swissmedic Signature Session - Towards Access 2030: How Can Strengthening of Regulatory Systems Contribute?

Chair(s):
Petra Doerr, PharmD, PhD, RPh
Deputy Executive Director
Swissmedic, Switzerland

Murray M. Lumpkin, DIAFellow, MD, MSc
Deputy Director, Regulatory Affairs, Lead Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation, United States

Description:
Various initiatives and programs are under way to improve access to quality medicines in low- and middle-income countries (LMIC). An important component of achieving this goal is to strengthen the regulatory systems of those countries. Many stakeholders (and many resources) are involved and engaged. However, what does Regulatory Systems Strengthening (RSS) actually mean in the context of Access 2030 in LMICs and do all these efforts show tangible results? What are the outcomes we are trying to achieve through RSS and how can we improve these outcomes?

Presentation(s) & Speaker(s):
Towards access 2030: An Overview of WHO Efforts in Regulatory Systems Strengthening
Emer Cooke, MBA
Head of Regulation of Medicines and other Health Technologies
World Health Organization (WHO) , Switzerland

What Can Regulators in LMIC Do to Better Utilize the Scarce Resources in Order to Improve the Access to Priority Medicines?
Delese Mimi Darko, MBA, RPh, RAC
Chief Executive Officer
Food and Drugs Authority, Ghana

Panel Discussion
Thomas B. Cueni, MBA
Director General
IFPMA, Switzerland

Panel Discussion
Petra Doerr, PharmD, PhD, RPh
Deputy Executive Director
Swissmedic, Switzerland

Panel Discussion
Guido Rasi, MD
Executive Director
European Medicines Agency (EMA), United Kingdom

Panel Discussion
Nicola Bedlington
Secretary General
European Patient's Forum, Belgium

Panel Discussion
Alex Schulze
Co-Head Division Global Programme Health
Swiss Agency For Development Cooperation, Switzerland

Panel Discussion
Hiiti Sillo
Director General
Tanzania Food & Drug Authority (TFDA), Tanzania, United Republic of

Panel Discussion
Nathalie Strub Wourgaft
Medical Director
Drugs For Neglected Diseases Initiative (dndi), Switzerland